Keros Therapeutics, Inc. (KROS) is a publicly traded company in the Unknown sector. Across all available filings, 18 corporate insiders have executed 473 transactions totaling $288.0M, demonstrating a bearish sentiment with -$195.6M in net insider flow. The most recent transaction on Nov 21, 2025 involved a transaction of 130,494 shares valued at $2.3M.
No significant insider buying has been recorded for KROS in the recent period.
No significant insider selling has been recorded for KROS in the recent period.
Based on recent SEC filings, insider sentiment for KROS is bearish with an Insider Alignment Score of 16/100 and a net flow of -$195.6M. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
Insider trading at Keros Therapeutics, Inc. (KROS) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 18 insiders are actively trading KROS stock, having executed 473 transactions in the past 90 days. The most active insider is Daniel Schneeberger (Executive), who has made 3 transactions totaling $95.7M.
Get notified when executives and directors at KROS file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Nov 21, 2025 | Knowles Julius | Executive | Disposition | 130,494 | $17.75 | $2.3M | Large |
| Nov 21, 2025 | Knowles Julius | Executive | Disposition | 191,527 | $17.75 | $3.4M | Large |
| Nov 21, 2025 | L. Gordon Carl | Executive | Disposition | 140,057 | $17.75 | $2.5M | Large |
| Nov 21, 2025 | L. Gordon Carl | Executive | Disposition | 74,465 | $17.75 | $1.3M | Large |
| Nov 21, 2025 | Gp Llc Orbimed Genesis | Executive | Disposition | 74,465 | $17.75 | $1.3M | Large |
| Nov 21, 2025 | Gp Llc Orbimed Genesis | Executive | Disposition | 140,057 | $17.75 | $2.5M | Large |
| Oct 15, 2025 | Schneeberger Daniel | Executive | Sale | 743,358 | $17.75 | $13.2M | Large |
| Oct 15, 2025 | Schneeberger Daniel | Executive | Sale | 4,391,237 | $17.75 | $77.9M | Large |
| Oct 15, 2025 | Schneeberger Daniel | Executive | Sale | 254,669 | $17.75 | $4.5M | Large |
| Oct 15, 2025 | IV L.p. Pontifax (china) | Executive | Sale | 1,121,045 | $17.75 | $19.9M | Large |
| Oct 15, 2025 | IV L.p. Pontifax (china) | Executive | Sale | 1,226,412 | $17.75 | $21.8M | Large |
| Oct 15, 2025 | IV L.p. Pontifax (china) | Executive | Sale | 155,262 | $17.75 | $2.8M | Large |
| Oct 15, 2025 | IV L.p. Pontifax (china) | Executive | Sale | 2,284,612 | $17.75 | $40.6M | Large |
| Sep 3, 2025 | Seehra Jasbir | Executive | Award | 90,500 | $N/A | $0 | |
| Aug 13, 2024 | Gp Llc Orbimed Genesis | Executive | Sale | 220,600 | $44.01 | $9.7M | Large |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Sale(S) | 339 | $241.8M | 79.9% |
Purchase(P) | 30 | $46.2M | 15.3% |
Disposition(D) | 6 | $13.3M | 4.4% |
Exercise(M) | 38 | $1.4M | 0.5% |
Award(A) | 1 | $0 | 0.0% |
Exercise (Options)(X) | 9 | $0 | 0.0% |
Conversion(C) | 50 | $0 | 0.0% |
Insider selling pressure at Keros Therapeutics, Inc. has increased, with 18 insiders executing 473 transactions across all time. Total sales of $241.8M significantly outpace purchases of $46.2M, resulting in a net outflow of $195.6M. This selling activity appears largely discretionary, which may warrant closer attention from investors.